Key Points
Analysts expect $0.29 EPS and $7.16B revenue for Q1 2026.
Recent quarter showed revenue beat but EPS miss, indicating margin compression.
Meyka AI rates MDLN B+ with 17 buy ratings supporting stock.
Investors should focus on margin guidance and 2026 forward outlook.
Medline Inc. (MDLN) will report first quarter earnings on May 6, 2026, at 12:30 PM ET. The medical device and supplies company faces investor scrutiny as it navigates post-IPO expectations. Analysts project earnings of $0.29 per share and revenue of $7.16 billion. The stock has declined 1.25% recently, trading at $44.19. With 17 buy ratings and only 2 holds from analysts, the market remains optimistic. Understanding what to expect from this earnings preview helps investors prepare for potential market moves.
Earnings Estimates and Historical Performance
Medline’s earnings preview shows mixed signals when compared to recent results. Analysts expect $0.29 EPS for Q1 2026, down from $0.238 EPS estimated in the prior quarter. Revenue estimates of $7.16 billion represent a decline from the previous quarter’s $7.51 billion estimate.
Recent Quarter Results
In Q4 2025, Medline missed EPS expectations by posting negative $0.01 earnings versus the $0.238 estimate. However, the company beat revenue expectations significantly, delivering $7.787 billion against a $7.512 billion estimate. This revenue beat of $275 million demonstrates strong operational execution despite earnings pressure.
Trend Analysis
The earnings preview reveals a concerning trend in per-share profitability. EPS estimates have declined from $0.238 to $0.29, suggesting margin compression or higher share counts. Revenue estimates also show sequential decline, which may reflect seasonal patterns or market headwinds in the medical supplies sector.
What Analysts Expect
The consensus among 17 buy-rated analysts suggests confidence in Medline’s long-term prospects. However, the earnings preview indicates near-term profitability challenges. Investors should monitor whether management addresses margin pressures during the earnings call.
Key Metrics and Financial Health
Medline’s financial position reveals a company managing significant debt while maintaining operational efficiency. The earnings preview shows mixed financial metrics that warrant careful analysis.
Profitability and Margins
Net profit margin stands at 4.07%, indicating modest profitability relative to revenue. Operating margin of 7.80% shows the company generates reasonable returns before financing costs. However, the earnings preview suggests these margins face pressure, with net income declining 3.4% year-over-year despite revenue growth of 11.5%.
Debt and Leverage
Debt-to-equity ratio of 1.17 indicates moderate leverage. The company carries $10.6 billion in net debt against a $35.89 billion market cap. Interest coverage of 3.29x provides adequate cushion for debt service. The earnings preview shows debt declined 25.7% year-over-year, a positive sign for financial stability.
Cash Flow Strength
Free cash flow per share of $2.15 demonstrates solid cash generation. Operating cash flow grew despite earnings pressure, suggesting quality earnings. The earnings preview indicates the company maintains strong working capital with a current ratio of 4.29x, well above the 1.5x safety threshold.
Beat or Miss Prediction
Based on historical patterns and current estimates, Medline faces a challenging earnings preview for Q1 2026.
Historical Beat/Miss Pattern
Medline’s most recent quarter showed a revenue beat but EPS miss. The company delivered $7.787 billion in revenue versus $7.512 billion expected, a 3.7% beat. However, EPS came in at negative $0.01 versus $0.238 expected, a significant miss. This pattern suggests operational strength but profitability challenges.
Earnings Preview Outlook
The earnings preview indicates higher probability of an EPS miss. Declining EPS estimates from prior quarters suggest analyst downgrades. Revenue estimates of $7.16 billion appear conservative relative to recent performance, potentially favoring a revenue beat. However, margin compression poses downside risk to earnings.
Risk Factors
The earnings preview highlights several risks: rising labor costs in healthcare, supply chain pressures, and competitive pricing dynamics. Medline’s gross profit margin of 24.6% provides buffer, but operating leverage appears limited. Investors should prepare for potential earnings disappointment despite revenue strength.
What Investors Should Watch
The earnings preview identifies critical areas requiring investor attention during the May 6 earnings release.
Margin Guidance and Commentary
Management commentary on gross margin trends will be crucial. The earnings preview shows gross profit grew 19.5% while net income declined 3.4%, indicating margin compression at lower levels. Listen for explanations regarding pricing power, input costs, and operational efficiency initiatives.
Segment Performance
Medline operates two segments: Medline Brand and Supply Chain Solutions. The earnings preview should clarify which segment drives growth and profitability. Investors need clarity on whether margin pressure is temporary or structural.
Forward Guidance
Management’s updated guidance for 2026 will heavily influence stock reaction. The earnings preview suggests cautious positioning, so any upside guidance could trigger positive response. Watch for commentary on healthcare spending trends, hospital capital budgets, and international expansion opportunities.
Cash Flow and Capital Allocation
With strong free cash flow generation, investors should monitor capital allocation priorities. The earnings preview shows zero dividend payout, suggesting management prioritizes debt reduction or reinvestment. Clarity on debt paydown pace and acquisition strategy matters for long-term value creation.
Final Thoughts
Medline Inc.’s May 6, 2026 earnings preview shows mixed signals. Analysts expect $0.29 EPS and $7.16 billion revenue, with a track record of revenue beats but EPS misses. The company has strong revenue growth and cash flow but faces margin compression hurting profitability. Meyka AI rates MDLN as B+. With 17 buy ratings, investors should monitor management’s margin outlook and 2026 guidance. Success depends on executing profitability improvements to maintain recent stock momentum.
FAQs
What EPS and revenue do analysts expect from Medline’s May 6 earnings?
Analysts expect Medline to report $0.29 earnings per share and $7.16 billion in revenue for Q1 2026. These estimates represent declines from prior quarter estimates, reflecting margin pressure concerns in the medical supplies sector.
Did Medline beat or miss earnings in the last quarter?
Medline missed EPS expectations in Q4 2025, posting negative $0.01 versus $0.238 estimated. However, the company beat revenue expectations significantly, delivering $7.787 billion against $7.512 billion estimated, showing operational strength.
What is Medline’s Meyka AI grade and what does it mean?
Meyka AI rates MDLN with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects balanced fundamentals but suggests caution on valuation.
What should investors watch during Medline’s earnings call?
Investors should monitor gross margin trends, segment performance breakdown, 2026 forward guidance, and capital allocation priorities. Management commentary on pricing power and cost pressures will be critical for assessing profitability sustainability.
Will Medline likely beat or miss earnings on May 6?
Based on historical patterns, Medline faces higher probability of an EPS miss but potential revenue beat. Declining EPS estimates suggest margin compression, though operational strength may support revenue expectations. Execution on profitability will determine actual results.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)